Abstract TP180: Characteristics and Outcomes of Cerebral Venous Sinus Thrombosis Associated With COVID-19
Adrian Scutelnic,Anita van de Munckhof,Angel Miaclin,SANJITH AARON,Sajid Hameed,Muhammad Wasay,Oxana Grosu,Katarzyna Krzywicka,Mayte Sanchez van Kammen,Erik Lindgren,Tiago Hom Moreira,Roberto Acampora,Negro Alberto,Theodoros KARAPANAYIOTIDES,Zedde Marialuisa,Shadi Yaghi,Barbera Ana,Elisa Cuadrado Godia,Paolo La Spina,Grillo Francesco,Fabrizio GIamello,Thanh Nguyen,Mohamad Abdalkader,Buture Alina,Nicolas raposo,Georgios Tsivogoulis,Paolo Candelaresi,Espen Saxhaug Kristoffersen,Antonio Ciacciarelli,Joshua Mbroh,Antonenko Katheryna,Johanna A. Kremer Hovinga,Tatjana Batenkova,Pasquale Scoppettuolo,Katarina Jood,Diana Aguiar De Sousa,Sven Poli,Turgut Tatlisumak,Jukka Putaala,Jonathan M Coutinho,Jose Ferro,Marcel Arnold,Mirjam Heldner
DOI: https://doi.org/10.1161/str.55.suppl_1.tp180
IF: 10.17
2024-02-01
Stroke
Abstract:Background: Coronavirus disease 2019 (COVID-19) increases the risk of cerebral venous sinus thrombosis (CVST), and previous reports derived from small case series reported a high mortality in these patients, up to 40%. We assessed the clinical characteristics and outcomes in an international cohort of patients with COVID-CVST. Methods: This was a registry study of consecutive COVID-CVST patients diagnosed between March 2020 and March 2023. As a comparison, we used data of patients with CVST unrelated to COVID-19,diagnosed between 2017 and 2018 and derived from the International Cerebral Venous Thrombosis Consortium database. Results: We included 70 patients with COVID-CVST from 23 hospitals in 15 countries and 206controls from 14 hospitals in 13 countries. Median age did not differ between the groups (43 vs 44years, P =0.6) but there were fewer women in the COVID-CVST group (50% vs 68%, P <0.01). The COVID severity was asymptomatic, mild or moderate in 60/69 (87%). The median thrombus load was higher in COVID-CVST patients (3 [IQR 2-4] vs 2 [1-3], P <0.01), as was the frequency of non-hemorrhagic brain lesions (47% vs 33%, P =0.03). The length of hospital stay in COVID-CVST patients was longer compared to controls (11 days [IQR 7-20] vs 8 [4-15], P =0.02). In-hospital mortality did not differ (5/67 [7%] vs 7/206 [3%], aORsex,age 2.5 [95%CI 0.7-9]), nor did the frequency of favorable clinical outcome (modified Rankin Scale 0-2, 45/56 [80%] vs 161/185 [87%], aORsex,age0.6 [0.2-1.7]) after 6 months. Conclusion: Contrary to previous reports, there was no significant difference in in-hospital mortality and long-term outcome in patients with COVID-CVST compared to patients with CVST unrelated toCOVID-19.
peripheral vascular disease,clinical neurology